Analyst Ratings for Tonix Pharmaceuticals
Tonix Pharmaceuticals Questions & Answers
The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Cantor Fitzgerald on August 12, 2022. The analyst firm set a price target for $4.00 expecting TNXP to rise to within 12 months (a possible 185.71% upside). 100 analyst firms have reported ratings in the last year.
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Cantor Fitzgerald, and Tonix Pharmaceuticals initiated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a initiated with a price target of $0.00 to $4.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $1.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.